I-Mab Inc. (NASDAQ: IMAB) stock gained by 0.31% at the last close however the IMAB stock price remains unchanged during after-hour. I-Mab is a fast-growing, worldwide biotech business dedicated to discovering, developing, and commercializing innovative or substantially differentiated biologics in the fields of immuno-oncology and autoimmune illnesses.
IMAB stock’ Significant Update
I-Mab has confirmed the opening of a new Translational Medicine and Formulation Research lab in San Diego. The company’s global development skills will be strengthened by the state-of-the-art, integrated laboratory and office facility. It will strengthen I-ability Mab’s to undertake global clinical trials in China and the United States.
I-Mab, which was founded in 2016, is dedicated to bringing breakthrough cancer medicines to patients across the world, leveraging the Company’s technical expertise in immuno-oncology and its broad pipeline of 20 unique assets in production. The San Diego location will be one of I-critical Mab’s drug development centers and will contain a complete biomarker platform to support ongoing and prospective clinical studies. The recent research facility will be part of I-US Mab’s R&D Center, along with the Worldwide Clinical Development location in Gaithersburg, Maryland, which focuses on worldwide clinical development and regulatory affairs and was created in 2018.
Moreover,
The firm is making large investments in the United States to assist the production of its creative pipeline in order to prepare for fast expansion over the next two years. In addition to acquiring essential people, the facility will function as a specialist research site for global development operations.
Dr. Jingwu Zang, Founder, Chairman and Director of I-Mab stated,
Their goal for the new San Diego site is to build the best research and operating facility as part of the I-Mab US R&D Center, which will help them in achieving their aim of providing first-in-class medications to patients throughout the world. They’re really enthusiastic about their new research facility in San Diego, which will enhance the worldwide research and development resources in order to accelerate their creative pipeline.
